What Medsol does

Medsol India Overseas Pvt. Ltd. is a privately held Indian pharmaceutical company founded in 2010 and headquartered in Noida, with 51–100 employees. The company focuses on the osteoporosis therapeutic segment, marketing a branded portfolio of generic bisphosphonate formulations including Alensol (Alendronate), Alensol-D (Alendronate + Vitamin D), Osteoplus (Risedronate), and Ibanplus (Ibandronic acid), with Zolendronic Acid (Vertesol) in development. Adjacent products include the pain reliever Tremsol (Tramadol/Acetaminophen), the GI therapy Paro-D (Pantoprazole/Domperidone), and dietary supplements Fresh-AD and Calcite.

Medsol operates a sales-led go-to-market through a direct field force of Medical Sales Representatives that engages doctors, hospitals, and pharmacies across India, with no disclosed international sales. The company complements its product business with three additional service lines: patient education and support (medication reminders, meal planning, lifestyle management delivered in hospital and home settings), pharmaceutical sales force capability training (product training, sales training, territory management), and prescription-channel distribution of branded products.

The company is founder-owned (established by three pharmaceutical industry professionals), with no disclosed external funding, acquisitions, partnerships, patents, or awards in the available data. Pricing is not publicly disclosed, and revenue figures have not been reported. The stated strategic vision is to rank among the top 50 pharmaceutical companies in India and pursue leadership in chosen global markets, though current operations remain concentrated in the domestic Indian market.

Name

Medsol

Legal name

Medsol India Overseas Pvt. Ltd.

Website

https://medsolindia.com

Company type

Private

Founded year

2010

Operating status

Operating

Headcount range

51–100 employees

Short description

Medsol India Overseas Pvt. Ltd. is a privately held Indian pharmaceutical company founded in 2010 that markets branded generic bisphosphonate formulations focused on osteoporosis, alongside pain, GI, and supplement products, selling to doctors, hospitals, and pharmacies through a direct field sales force in India.

Ownership category

akta.pro rank

Headquarters

HQ city

Noida

HQ country

India

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Marketing or Sales, Personnel, Operations, Technology or R&D

Revenue model

1. Pharmaceutical Products: Sale of branded pharmaceutical products including osteoporosis medications (Alendronate, Risedronate, Ibandronic acid), pain relievers (Tramadol/Acetaminophen), and supplements. Products are sold to healthcare providers and patients through prescription channel.
2. Training Services: Sales force capability building through product training, sales training, territory management, and pre-interview training seminars for pharmaceutical sales professionals.
3. Patient Education Services: Patient education and support services including medication reminders, meal planning, and lifestyle management programs delivered in hospital and home settings.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

Medsol develops, manufactures, and markets branded pharmaceutical formulations with a primary focus on the osteoporosis therapeutic segment, including bisphosphonate products (Alensol/Alendronate, Osteoplus/Risedronate, Ibanplus/Ibandronic acid) and combination products such as Alensol-D (Alendronate + Vitamin D). Alongside prescription drugs, the company sells pain management (Tremsol), gastrointestinal (Paro-D), and dietary supplement products (Fresh-AD, Calcite). Medsol also delivers patient education and support services in hospital and home settings, and provides pharmaceutical sales force capability training (product training, sales training, territory management).

Product overview

Medsol is a pharmaceutical company focused on the Osteoporosis therapeutic segment. The company offers a portfolio of bisphosphonate medications including Alensol™ (Alendronate), Osteoplus™ (Risedronate), Ibanplus™ (Ibandronic acid), and combination products like Alensol-D™ and Paro-D™. In addition to prescription medications, Medsol markets dietary supplements including Fresh-AD™ (vitamins, minerals & Ginseng) and Calcite™ (calcium & Vit D). The company also provides healthcare services including patient education programs, medication reminders, meal planning, lifestyle management, and comprehensive sales force training services for the pharmaceutical industry.

Differentiator

Problem solved

Functional benefit

Products and services

• Alensol
• Alensol-D
• Osteoplus
• Ibanplus
• Tremsol
• Paro-D
• Fresh-AD
• Calcite
• Patient Education and Support Services
• Pharmaceutical Sales Force Capability Training

Segments2 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators3 records

Recent moves5 records

Expansion highlights4 records

Direct peers

• Ipca Laboratories: Indian formulation-driven pharma with branded generics portfolio covering chronic and therapeutic areas; comparable in sales-led distribution model and India-domestic revenue mix.
• Emcure Pharmaceuticals: India-based mid-sized pharma with branded formulations, women's health, and chronic-disease therapies; comparable scale and specialty-care orientation.
• Alkem Laboratories: Mid-tier Indian listed pharma company specializing in branded generics across multiple therapeutic areas, with strong direct field-sales presence and a specialty-chronic-disease portfolio that overlaps with Medsol's osteoporosis franchise.
• USV Private Limited: India-based, founder-owned mid-size pharma company with branded formulations across specialty therapeutic areas including osteoporosis (Ibandronate). Closest comparable on size, ownership profile (private), branded-generic focus, and India-only footprint.
• Eris Lifesciences: Indian specialty pharma focused on chronic-disease branded formulations sold through specialist field force; highly comparable chronic-care specialty positioning and sales model to Medsol.
• Macleods Pharmaceuticals: Private Indian pharma company with a broad branded-generics portfolio sold through field sales force to physicians and hospitals. Similar size bracket, founder-led, multi-therapeutic branded focus, and direct sales-led GTM.

Regional players

• Alembic Pharmaceuticals: Indian branded-generics pharma with specialty and chronic-care therapeutic areas; comparable in formulation focus and India field-sales distribution model.
• Natco Pharma: India-headquartered specialty pharma with branded oncology and chronic-disease formulations; relevant comparable for specialty branded strategy though larger and more diversified than Medsol.

Broad incumbents

• Cipla: One of India's largest pharmaceutical incumbents with broad branded-formulations portfolio covering respiratory, cardiology, and chronic-disease categories that include osteoporosis therapeutics.
• Mankind Pharma: One of India's largest domestic pharma companies with extensive branded generics portfolio across chronic and acute segments; broader scale and reach than Medsol but overlapping chronic-disease franchises.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/medsolindia
• LinkedInlinkedin.com/company/medsol-india-overseas-pvt-ltd

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Medsol